Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075.

Molecular cancer research : MCR - 1 Jan 2017

Faivre Emily J, Wilcox Denise, Lin Xiaoyu, Hessler Paul, Torrent Maricel, He Wei, Uziel Tamar, Albert Daniel H, McDaniel Keith, Kati Warren, Shen Yu

Abstract excerpt

Competitive inhibitors of acetyl-lysine binding to the bromodomains of the BET (bromodomain and extra terminal) family are being developed for the treatment of solid and hematologic malignancies. The function of BET family member BRD4 at enhancers/superenhancers has been shown to sustain signal-dependent or pathogenic gene expression programs. Here, the hypothesis was tested that the transcription factor drivers...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Androgen Antagonists
Share to Benzamides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dihydrotestosterone

Share to Inhibitory Concentration 50

Share to Nitriles

Share to Prostatic Neoplasms, Castration-Resistant

Share to Pyridones

Share to Receptors, Androgen

Source

Identifiers

PMID: 27707886
DOI: 10.1158/1541-7786.MCR-16-0221

Genes

BRD4
TMPRSS2
MYC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075.PMID 27707886Read ↗

Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC)Semantic proximity Read ↗

Maintenance of MYC expression promotes de novo resistance to BET bromodomain inhibition in castration-resistant prostate cancerSemantic proximity Read ↗

BET bromodomain inhibitors—A novel epigenetic approach in castration-resistant prostate cancerSemantic proximity Read ↗

Resistance to BET Inhibitor Leads to Alternative Therapeutic Vulnerabilities in Castration-Resistant Prostate CancerSemantic proximity Read ↗

Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate CancerSemantic proximity Read ↗

The Pioneering Role of GATA2 in Androgen Receptor Variant Regulation Is Controlled by Bromodomain and Extraterminal Proteins in Castrate-Resistant Prostate CancerSemantic proximity Read ↗

BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate CancerSemantic proximity Read ↗

Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancerSemantic proximity Read ↗

BET inhibitors in metastatic prostate cancer: therapeutic implications and rational drug combinationsSemantic proximity Read ↗

Targeting the BRD4-HOXB13 Coregulated Transcriptional Networks with Bromodomain-Kinase Inhibitors to Suppress Metastatic Castration-Resistant Prostate CancerSemantic proximity Read ↗

BET bromodomain-mediated interaction between ERG and BRD4 promotes prostate cancer cell invasionSemantic proximity Read ↗

Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.